Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113081 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4CYP2C9 | |
| SCHEMBL4107246 | 0.94 | NR3C1 (1.00) | NR3C1PGRCYP3A4CYP2C9 | |
| SCHEMBL4123689 | 0.92 | NR3C1 (1.00) | NR3C1PGRCYP3A4CYP2C9 | |
| SCHEMBL4114782 | 0.92 | NR3C1 (1.00) | NR3C1PGRCYP3A4CYP2C9 | |
| SCHEMBL4119637 | 0.91 | NR3C1 (1.00) | NR3C1PGRCYP3A4CYP2C9 | |
| SCHEMBL4120184 | 0.91 | NR3C1 (1.00) | NR3C1PGRCYP3A4CYP2C9 | |
| SCHEMBL5138011 | 0.91 | NR3C1 (1.00) | NR3C1PGRCYP3A4CYP2C9 | |
| SCHEMBL4124035 | 0.91 | NR3C1 (1.00) | NR3C1PGRCYP3A4CYP2C9 | |
| SCHEMBL4120158 | 0.91 | NR3C1 (1.00) | NR3C1PGRCYP3A4CYP2C9 | |
| SCHEMBL4106106 | 0.90 | NR3C1 (0.86) | NR3C1PGRCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940800-A1 | NOVEL BICYCLIC SULFONAMIDES FOR USE AS GLUCOCORTICOID RECEPTOR MODULATORS IN THE TREATMENT OF INFLAMMATORY DISEASES | Astra Zeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007046747-A1 | NOVEL BICYCLIC SULFONAMIDES FOR USE AS GLUCOCORTICOID RECEPTOR MODULATORS IN THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | WO | disclosed |